Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Absolute Bioavailability Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

NCT01301092
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
LY2189265
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

NCT06433505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, [14C] BMS-986365, [14C] BMS-986409 + BMS-986410, [14C] BMS-986410 + BMS-986409
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Lidocaine in Healthy Adults

NCT03310970
View directory record Official record
Conditions
Healthy
Interventions
Lidocaine 5% patch, Lidocaine hydrochloride, Lidoderm 5% patch
Drug
Lead sponsor
Nicole K Brogden
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

NCT01582399
View directory record Official record
Conditions
Pharmacokinetics of ASKP1240, Pharmacodynamics of ASKP1240, Healthy Volunteers
Interventions
ASKP1240
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

NCT04983732
View directory record Official record
Conditions
Healthy Subjects
Interventions
FL-101-Intravenous, FL-101-Subcutaneous
Drug
Lead sponsor
Flame Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Oral Bioavailability of Remimazolam

NCT04113564
View directory record Official record
Conditions
Bioavailability
Interventions
Remimazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

NCT05630677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional

Absolute Bioavialability of GSK1120212

NCT01416337
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK1120212B
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants

NCT02079545
View directory record Official record
Conditions
Healthy
Interventions
Sirukumab (IV infusion), Sirukumab (SC injection with PFS-U), Sirukumab (SC injection with PFS-AI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of The Absolute Bioavailability of TH104

NCT06198686
View directory record Official record
Conditions
Healthy
Interventions
Nalmefene
Drug
Lead sponsor
Tharimmune Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

NCT02169583
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

NCT07185321
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Mosliciguat, 14C mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

NCT06691828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

NCT07780383
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Participants
Interventions
BMS-986446
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Subcutaneous Lecanemab in Healthy Participants

NCT05045716
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lecanemab
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

NCT05005338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

NCT05730842
View directory record Official record
Conditions
Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn
Interventions
EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]-LOXO-783 in Healthy Adult Participants

NCT06102512
View directory record Official record
Conditions
Healthy
Interventions
[¹⁴C]-LOXO-783, LOXO-783
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 4, 2026, 4:08 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability Study With Bexagliflozin

NCT03417076
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

NCT03703505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-348, [13C6]AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults

NCT07423286
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Oral [14C] PF-07248144, Oral unlabeled PF-07248144, IV [14C] PF-07248144
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]-LY4064809 in Healthy Participants

NCT07519525
View directory record Official record
Conditions
Healthy
Interventions
LY4064809, [14C]-LY4064809
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lofexidine ADME & Mass Balance in Volunteers

NCT01310296
View directory record Official record
Conditions
Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product
Interventions
Lofexidine hydrochloride
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 4, 2026, 4:08 PM EDT